Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
NCT07218029 · View on ClinicalTrials.gov ↗
Study Summary
Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) treatments for PAH can treat symptoms of PAH but do not stop PAH from getting worse. Sotatercept is a study medicine designed to treat PAH. It is a targeted therapy, which is a treatment that works on certain proteins that play a role in causing PAH. This is a long-term follow-up (LTFU) study. People who took part in certain other studies testing sotatercept for PAH may be able to join this study. The goal of this study is to learn about the long-term safety of sotatercept and if people tolerate it when taken with standard PAH treatment over a longer period of time.
Conditions Studied
Interventions
- BIOLOGICAL Sotatercept
Study Locations (20)
California
- University of California San Diego Health ( Site 1002) — La Jolla
- UCSF Helen Diller Medical Center at Parnassus Heights ( Site 1019) — San Francisco
- Jeffrey S. Sager, MD Medical Corporation ( Site 1060) — Santa Barbara
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ( Site 1028) — Torrance
Ohio
- The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001) — Cincinnati
- University of Cincinnati Medical Center ( Site 1035) — Cincinnati
- Ohio State University Wexner Medical Center ( Site 1032) — Columbus
Arizona
- Pulmonary Associates, PA ( Site 1008) — Phoenix
Colorado
- University of Colorado Hospital ( Site 1013) — Aurora
Florida
- Mayo Clinic Jacksonville ( Site 1045) — Jacksonville
Kansas
- University of Kansas Medical Center ( Site 1020) — Kansas City
Kentucky
- Norton Pulmonary Specialists ( Site 1066) — Louisville
Massachusetts
- Tufts Medical Center ( Site 1012) — Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 815 participants |
| Start Date | 2021-05-12 |
| Est. Completion | 2028-12-07 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218029
The ClinicalTrials.gov registry entry for NCT07218029 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 815 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 741 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention — of which Sotatercept is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07218029 reports 20 study locations spanning 15 distinct geographic areas — top geographies include California, Ohio, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07218029 about?
NCT07218029 is a clinical study titled "A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)". Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) trea...
What is the current status of trial NCT07218029?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 815 participants. The study started on 2021-05-12. Estimated completion is 2028-12-07.
What conditions does trial NCT07218029 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07218029?
The interventions under investigation include: Sotatercept (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07218029?
This trial is sponsored by Merck Sharp & Dohme, which has 741 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07218029 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.